Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner.

Tripartite motif protein 32 (TRIM32), an E3 ubiquitin ligase, has been reported to participate in many human cancers. However, the underlying role of TRIM32 in glioma remains largely unknown. Here, we aimed to explore the function of TRIM32 in glioma cells and the clinical implications and found that TRIM32 was ...
upregulated in glioma tissues. Consistently, overexpression of TRIM32 promoted glioma U87 and U251 cell proliferation and conferred cell resistance to temozolomide (TMZ). Conversely, knockdown of TRIM32 inhibited glioma cells proliferation in vitro and in vivo and sensitized glioma cells to the treatment of TMZ in a p53-dependent and -independent manner. Mechanistically, knockdown of TRIM32 induced apoptosis of U87 an U251 cells. In addition, TRIM32 interacted with the antiapoptotic proteins BCL-xL and BCL-w, which antagonized the inhibitory effect of TRIM32 knockdown in U87 cells. Together, our study uncovered the role of TRIM32 in glioma and TRIM32 may be a potential therapeutic target for gliomas.
Mesh Terms:
Animals, Apoptosis, Apoptosis Regulatory Proteins, Cell Line, Tumor, Cell Proliferation, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Glioma, Humans, Mice, Molecular Targeted Therapy, Neoplasm Grading, Temozolomide, Transcription Factors, Tripartite Motif Proteins, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases, Up-Regulation, Xenograft Model Antitumor Assays
Biochem Biophys Res Commun
Date: Dec. 23, 2020
Download Curated Data For This Publication
231808
Switch View:
  • Interactions 2